AZATHIOPRINE TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

AZATHIOPRINE

Tersedia dari:

SANIS HEALTH INC

Kode ATC:

L04AX01

INN (Nama Internasional):

AZATHIOPRINE

Dosis:

50MG

Bentuk farmasi:

TABLET

Komposisi:

AZATHIOPRINE 50MG

Rute administrasi :

ORAL

Unit dalam paket:

100

Jenis Resep:

Prescription

Area terapi:

IMMUNOSUPPRESSIVE AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0101830001; AHFS:

Status otorisasi:

CANCELLED POST MARKET

Tanggal Otorisasi:

2017-07-31

Karakteristik produk

_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
AZATHIOPRINE
AZATHIOPRINE TABLETS USP
50 MG
IMMUNOSUPPRESSIVE AGENT
SANIS HEALTH INC.
333 CHAMPLAIN ST.
DIEPPE, NEW BRUNSWICK
DATE OF PREPARATION:
E1A 1P2
July 7, 2015
CONTROL #: 184965
_____________________________________________________________________________________
_AZATHIOPRINE Product Monograph _
_Page 2 of 25_
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL INFORMATION
..............................................
3
SUMMARY PRODUCT INFORMATION
......................................................
3
INDICATIONS AND CLINICAL USE
............................................................
3
CONTRAINDICATIONS
.................................................................................
3
WARNINGS AND PRECAUTIONS
................................................................
4
ADVERSE REACTIONS
..................................................................................
8
DRUG INTERACTIONS
..................................................................................
10
DOSAGE AND ADMINISTRATION
..............................................................
12
OVERDOSAGE
................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................
13
STORAGE AND STABILITY
..........................................................................
15
SPECIAL HANDLING INSTRUCTIONS
.......................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING .............................
15
PART II: SCIENTIFIC INFORMATION
........................................................................
16
PHARMACEUTICAL INFORMATION
..........................................................
16
CLINICAL TRIALS
..........................................................................................
16
TOXICOLOGY
.....................